(Q34101953)

31 July 2017

title

Adoptive immunotherapy for postoperative hepatocellular carcinoma: a systematic review (English)

1 reference

31 July 2017

1 reference

1 reference

hepatocellular carcinoma

1 reference

J-H Zhong

1

1 reference

31 July 2017

L Ma

2

1 reference

31 July 2017

L-C Wu

3

1 reference

31 July 2017

W Zhao

4

1 reference

31 July 2017

W-P Yuan

5

1 reference

31 July 2017

F-X Wu

6

1 reference

31 July 2017

Z-M Zhang

7

1 reference

31 July 2017

S Huang

8

1 reference

31 July 2017

X M You

9

1 reference

31 July 2017

L-Q Li

10

1 reference

31 July 2017

publication date

1 January 2012

1 reference

International Journal of Clinical Practice

31 July 2017

published in

1 reference

31 July 2017

volume

66

1 reference

31 July 2017

issue

1

1 reference

31 July 2017

page(s)

21-27

1 reference

Hepatocellular carcinoma: recent trends in the United States

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02814.X

Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02814.X

Hepatocellular cancer: a guide for the internist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02814.X

Global cancer statistics, 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02814.X

Endoscopic Ultrasound and Fine-needle Aspiration for the Diagnosis of Hepatocellular Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02814.X

Pre-operative liver biopsy in cirrhotic patients with early hepatocellular carcinoma represents a safe and accurate diagnostic tool for tumour grading assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02814.X

Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: A retrospective study of hepatitis C virus-related liver cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02814.X

Predictors of microvascular invasion before hepatectomy for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02814.X

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02814.X

Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: A meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02814.X

Is there a role for adjuvant treatment after hepatic resection for hepatocellular carcinoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02814.X

Dendritic cells fused with allogeneic hepatocellular carcinoma cell line compared with fused autologous tumor cells as hepatocellular carcinoma vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02814.X

Is there a role for immunotherapy in hepatocellular carcinoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02814.X

Immunotherapeutic strategies for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02814.X

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02814.X

Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02814.X

Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02814.X

Therapeutic safety and effects of adjuvant autologous RetroNectin activated killer cell immunotherapy for patients with primary hepatocellular carcinoma after radiofrequency ablation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02814.X

Medical treatments for hepatocellular carcinoma (HCC): what's next?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02814.X

Current status of adoptive immunotherapy of malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02814.X

Adoptive immunotherapy of cancer using activated autologous lymphocytes--current status and new strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02814.X

Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02814.X

Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02814.X

Immunoregulation of dendritic and T cells by alpha-fetoprotein in patients with hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02814.X

Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02814.X

Possibility of adoptive immunotherapy with peripheral blood-derived CD3⁻CD56+ and CD3+CD56+ cells for inducing antihepatocellular carcinoma and antihepatitis C virus activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02814.X

T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02814.X

Transfusion of autologous cytokine-induced killer cells inhibits viral replication in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02814.X

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02814.X

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02814.X

Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02814.X

Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02814.X

Radiofrequency Thermal Ablation for Hepatocellular Carcinoma Stimulates Autologous NK-Cell Response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02814.X

10.1111/J.1742-1241.2011.02814.X

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference